An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
- Conditions
- Post Intensive Care Syndrome (PICS)Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Other: An ICU admission and a temporally related ARDS diagnosis
- Registration Number
- NCT06272942
- Lead Sponsor
- Bayer
- Brief Summary
This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied.
ARDS is a life-threatening condition in which fluid builds up in the lungs making breathing difficult.
In observational studies, only observations are made without participants receiving any advice or any changes to health care.
People who are admitted to ICU for serious illnesses, like ARDS, often experience new health problems during and after their ICU stays. These health problems that may include physical, mental, and/or emotional disorders, are called post-intensive care syndrome (PICS). Identifying these new health problems early can help people by timely treatments and care.
In this study, researchers want to identify any health problems that arise after ICU admission in people with ARDS in the United States (US). To do this, researchers will collect information on health problems, treatments, medicines, and healthcare visits in people with ARDS, 1 year before and after an ICU admission.
They will then look to see whether the health problems are in areas that have been described as the post intensive care syndrome (PICS).
In addition, they will measure healthcare related costs in the one year after admission and compare it to the one year prior to admission.
Researchers will also compare this information with data collected for people with pneumonia who did not require ICU admission. This will help them to identify any new health problems arising due to ICU stays.
The data will come from participants' medical claims information stored in the Optum Clinformatics Data Mart database from 2016 to 2022. The claims data will only be collected for people in the US.
Researchers will collect data from participants admitted to ICU for ARDS for a maximum of 1 year before and after their stay.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 140000
- continuous coverage of at least 365 days (>= 1 year) pre-index date for the cohort
- age >= 18 years
- not seen outside the healthcare system
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Post intensive care unit (ICU) morbidity An ICU admission and a temporally related ARDS diagnosis All adult patients in Optum Claims data from January 1, 2016 until October 1, 2022.
- Primary Outcome Measures
Name Time Method Morbidity at 1,3,6 and 12 month pre- and post- index hospital admission Morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.
Difference in prevalence rates pre versus post index hospitalization at 1, 3, 6 and 12 months post- index hospital admission Average total healthcare costs based on healthcare billing data in the one year post index ICU admission at 12 months post- index hospital admission Average total healthcare costs will be based on healthcare billing data in the one year post index ICU admission.
Post ICU Syndrome-related morbidity at 12 months post- index hospital admission PICS-related morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.
PICS stands for post intensive care unit syndrome.Incident morbidity at 1, 3, 6 and 12 months post- index hospital admission Incident morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.
Post ICU Syndrome-related incident morbidity at 1, 3, 6 and 12 months post- index hospital admission PICS-related incident morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Bayer
🇺🇸Whippany, New Jersey, United States